Shots:

• The P-IIIa (ONWARDS 3 & 4) trials evaluating efficacy & safety treat-to-target trial of insulin icodec (qw) vs insulin degludec & insulin glargine U100 in combination with mealtime insulin in 588 & 582 patients with T2D. The results from (ONWARDS 5) trial are expected in H2'22
• The P-IIIa (ONWARDS 3 & 4) trials meet its 1EPs & showed non-inferiority in reducing HbA1c @26wk. with insulin icodec over insulin degludec & insulin glargine
• Superior reduction in estimated HbA1c of –1.57% & –1.16% vs –1.36% & –1.18% from an overall baseline HbA1c of 8.5% & 8.3%, no significant difference in estimated rates of sev. or clinically significant hypoglycaemia with 0.31 & 5.64 vs 0.15 & 5.62 event per patient yr., was safe & well-tolerated

Ref: Globenewswire | Image: Novo Nordisk